Effect of Therapeutic and Supratherapeutic Oral Doses of... | NCT04563845

Label	Type	Description	Intervention Names
Part 1: Participants receiving placebo	Placebo Comparator	Participants will receive a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.	Drug: GSK3640254 Drug: Placebo
Part 1: Participants receiving GSK3640254 500 milligrams (mg)	Experimental	Participants will receive a single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	Drug: GSK3640254
Part 2: Main QTc Study	Experimental	Participants will be randomized to 1:1:1:1 ratio to receive Treatment T- Therapeutic dose of GSK3640254 (100 mg QD) on Days 1 through 7 or Treatment ST- Supratherapeutic dose of GSK3640254 (to be determined from Part 1) on Days 1 through 7 or Treatment P- Placebo for GSK3640254 on Days 1 through 7 or Treatment M- Moxifloxacin (GSK3640254 placebo Days 1 through 6 and a single dose of Moxifloxacin [400 mg] on Day 7 in 4 treatment periods. There will be at least 7 days wash out period between each period.	Drug: GSK3640254 Drug: Placebo Drug: Moxifloxacin

Name	Type	Description	Arm Group Labels	Other Names
GSK3640254	Drug	GSK3640254 will be administered.	Part 1: Participants receiving GSK3640254 500 milligrams (mg) Part 1: Participants receiving placebo

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) of GSK3640254	Blood samples were collected at indicated time points. Pharmacokinetic (PK) analysis was conducted using standard non-compartmental methods.	Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7
Part 1: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3640254	Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.	Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7
Part 1: Maximum Observed Concentration (Cmax) of GSK3640254	Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.	Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7
Part 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of GSK3640254	Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods	Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7
Part 1: Time of Maximum Observed Concentration (Tmax) of GSK3640254	Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Secondary Outcomes

Measure	Description	Time Frame
Part 2: Change From Baseline in Heart Rate (HR) - For GSK3640254 100 mg, GSK3640254 500 mg and Placebo Arms	Twelve-lead ECGs were recorded in participant using an automated ECG machine. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits.Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Other Outcomes

Measure	Description	Time Frame
Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm	Twelve-lead ECGs were recorded in participant using an automated ECG machine. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits.Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value

Eligibility Module

Eligibility Criteria

Inclusion criteria:

Participant must be 18 to 50 years of age inclusive, at the time of signing the informed consent.
Participants who are healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination (including cardiopulmonary examination), laboratory tests, and cardiac monitoring (history and ECG).
Body weight more than or equal to (>=)50.0 kilograms (kg) (110 pounds [lbs]) for men and >=45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 31.0 kilograms per square meter (kg/m^2) (inclusive).
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Male or female participants:
1. Male participants should not engage in intercourse while confined in the clinic. There is no need for an extended period of double barrier use or prolonged abstinence after study discharge.
2. Female participants:
(i) A female participant is eligible to participate if she is not pregnant, planning to become pregnant within the next 6 months, or breastfeeding, and at least 1 of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR Is a WOCBP and using a non-hormonal contraceptive method that is highly effective, with a failure rate of less than (<)1 percent (%) for 28 days before intervention, during the intervention period, and for at least 28 days after the last dose of study intervention. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.

(ii) A WOCBP must have a negative highly sensitive serum pregnancy test at Screening and Check-in.

Capable of giving signed informed, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol.

Exclusion criteria:

Participants with current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
A pre-existing condition interfering with normal Gastrointestinal (GI) anatomy or motility (for example [e.g.], gastro-esophageal reflux disease, gastric ulcers, gastritis), hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study intervention or render the participant unable to take oral study intervention.
Prior cholecystectomy (prior appendectomy is acceptable).
Clinically significant illness, including viral syndromes, within 3 weeks of dosing.
A participant with known or suspected active Coronavirus Disease-2019 (COVID-19) infection OR contact with an individual with known COVID-19, within 14 days of study enrollment (World Health Organization [WHO] definitions).
Any history of significant underlying psychiatric disorder, including, but not limited to, schizophrenia, bipolar disorder with or without psychotic symptoms, other psychotic disorders, or schizotypal (personality) disorder.
Any history of major depressive disorder with or without suicidal features, or anxiety disorders that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (more than [>]6 months) outpatient treatment. Participants with other conditions such as adjustment disorder or dysthymia that have required shorter term medical therapy (<6 months) without inpatient treatment and are currently well-controlled clinically or resolved may be considered for entry after discussion and agreement with the ViiV Healthcare/GlaxoSmithKline (VH/GSK) Medical Monitor.
Any pre-existing physical or other psychiatric condition (including alcohol or drug abuse), which, in the opinion of the investigator (with or without psychiatric evaluation), could interfere with the participant's ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the participant.
Medical history of cardiac arrhythmias, prior myocardial infarction in the past 3 months, or cardiac disease or a family or personal history of long QT syndrome.
History indicative of an increased risk of a cardiac arrhythmia or cardiac disease, including the following:
1. History of symptomatic cardiac arrhythmias or palpitations associated with pre-syncope or syncope, or history of unexplained syncope.
2. History of cardiac arrest.
3. History of clinically relevant cardiac disease including symptomatic or asymptomatic arrhythmias (including but not limited to ventricular fibrillation, ventricular tachycardia, any degree of atrioventricular block, Brugada syndrome, Wolff-Parkinson-White Syndrome, and sinus bradycardia, defined as HR less than 50 bpm based on vital signs or ECG), presyncope or syncopal episodes, or additional risk factors for torsades de pointes (e.g., heart failure).
4. History of clinically relevant structural cardiac disease including hypertrophic obstructive cardiomyopathy.
5. History of hypokalemia.
History of heart disease (e.g., coronary heart disease, angina).
Presence of hepatitis B surface antigen at Screening or within 3 months prior to starting study intervention.
Positive hepatitis C antibody test result at Screening or within 3 months prior to starting study intervention.
Positive Human Immunodeficiency virus (HIV)-1 and -2 antigen/antibody immunoassay at Screening.
Alanine aminotransferase (ALT) >=1.5 times upper limit of normal (ULN). A single repeat of ALT is allowed within a single Screening period to determine eligibility.
Bilirubin >=1.5 times ULN (isolated bilirubin >=1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). A single repeat of any laboratory abnormality is allowed within a single Screening period to determine eligibility.
Any acute laboratory abnormality (including hypokalemia, hypercalcemia, or hypomagnesemia) at Screening which, in the opinion of the investigator, should preclude participation in the study of an investigational compound.
Any Grade 2 to 4 laboratory abnormality at Screening, with the exception of lipid abnormalities (e.g., total cholesterol, triglycerides), and ALT (previously described), will exclude a participant from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the sponsor. A single repeat of any laboratory abnormality is allowed within a single Screening period to determine eligibility.
Urine drug screen positive (showing presence of): amphetamines, barbiturates, cocaine, Methylenedioxymethamphetamine (MDMA), cannabinoids, methamphetamines, phencyclidine, or non-prescribed opiates, oxycodone, benzodiazepines, methadone, or tricyclic antidepressants at screening or before dosing of study intervention.
Unable to refrain from the use of prescription or nonprescription drugs including vitamins, herbal and dietary supplements (including Saint [St] John's wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study intervention and for the duration of the study.
Treatment with any vaccine within 30 days prior to receiving study intervention.
Unwillingness to abstain from consumption of any food or drink containing grapefruit and grapefruit juice, Seville oranges, blood oranges, or pomelos or their fruit juices within 7 days prior to the first dose of study intervention(s) until the end of the study.
Participation in another concurrent clinical study or prior clinical study (with the exception of imaging trials) prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the study intervention (whichever is longer).
Prior exposure to GSK3640254 in this or another clinical study.
Prior intolerance to Moxifloxacin.
Prior participation in this clinical study (participants may not participate in both Part 1 and Part 2 of the study).
Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
Any positive (abnormal) response confirmed by the investigator on a screening clinician- or qualified designee-administered Columbia-Suicide Severity Rating Scale (C-SSRS).
A sustained supine systolic blood pressure >150 millimeters of mercury (mm Hg) or <90 mm Hg or a supine diastolic blood pressure >95 mm Hg or <50 mm Hg at Screening or Check-in (Day -2). Blood pressure may be retested once in the supine position. The blood pressure abnormality is considered sustained if either the systolic or the diastolic pressure values are outside the stated limits after 2 assessments, in which case the participant may not be randomized.
A resting HR of <50 bpm or >100 bpm when vital signs are measured at Screening or Check-in (Day -2). A HR from 100 to 110 bpm can be rechecked by ECG or vital signs within up to 2 hours to verify eligibility.
An uninterpretable ECG or any significant arrhythmia or ECG finding (e.g., prior myocardial infarction in the past 3 months, significant pathological Q-waves (defined as Q-wave >40 ms or depth greater than 0.4-0.5 millivolts [mV], symptomatic bradycardia, non-sustained or sustained atrial arrhythmias, ventricular pre-excitation, non-sustained or sustained ventricular tachycardia, any degree of atrioventricular block, complete left bundle branch block, or conduction abnormality) which, in the opinion of the investigator or VH/GSK Medical Monitor, will interfere with the safety of the individual participant.
Exclusion criteria for Screening ECG (a single repeat is allowed for eligibility determination):

(i) HR: <50 or >100 bpm (ii) QTcF interval1: >450 ms (iii) QRS interval: >110 ms (iv) PR interval: >200 ms
Screening Holter (24 hours) with any of the following:

(i) Sinus bradycardia less than or equal to (<=)35 bpm or junctional arrhythmia >60 bpm for 10 seconds or longer.

(ii) Non-sustained ventricular tachycardia or more than 30 ventricular premature depolarizations during an hour.

(iii) Atrial arrhythmia >100 bpm for 3 seconds or longer or more than 40 atrial premature depolarizations during an hour.

History of alcoholism and/or drug/chemical abuse or regular alcohol consumption within 6 months of screening, defined as an average weekly intake of >14 units. One unit is equivalent to 8 grams of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine, or 1 (25 mL) measure of spirits.
Unable to refrain from tobacco or nicotine-containing products within 3 months prior to Screening and for the duration of the study.
History of sensitivity to any of the study medications or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.

Name	Affiliation	Role
GSK Clinical Trials	ViiV Healthcare	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
GSK Investigational Site		Austin	Texas	78744	United States

PubMed Identifier	Type	Citation	Retractions
37961928	Derived	Zhang Y, Bush M, Yazdani P, Zhan J, Wen B, Bainbridge V, Wynne BR, Joshi S, Lataillade M. Effects of the HIV-1 maturation inhibitor GSK3640254 on QT interval in healthy participants. Pharmacol Res Perspect. 2023 Dec;11(6):e01151. doi: 10.1002/prp2.1151.

ID	Title	Description
FG000	Part 1: Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
FG001	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot	Yes	No	No	Study Protocol	Sep 10, 2020	Sep 20, 2022

Arm/Group Information

ID	Title	Description
BG000	Part 1: Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
BG001	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.
BG002	Part 2: GSK3640254 100 mg/GSK3640254 500 mg/Placebo/Moxifloxacin 400 mg	Participants received a single therapeutic dose of GSK3640254 100 mg once daily on Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg once daily on Days 1 through 7 (Treatment ST). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). There was a washout period of at least 7 days between each treatment periods.
BG003	Part 2: GSK3640254 500 mg/Moxifloxacin 400 mg/GSK3640254 100 mg/Placebo	Participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.
BG004	Part 2: Placebo/GSK3640254 100 mg/Moxifloxacin 400 mg/GSK3640254 500 mg	Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.
BG005	Part 2: Moxifloxacin 400 mg/Placebo/GSK3640254 500 mg/GSK3640254 100 mg	Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.
BG006	Part 2: GSK3640254 500 mg/Placebo/GSK3640254 100 mg/Moxifloxacin 400 mg	Participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7(Treatment M). There was a washout period of at least 7 days between each treatment periods.
BG007	Part 2: Placebo/Moxifloxacin 400 mg/GSK3640254 500 mg/GSK3640254 100 mg	Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.
BG008	Part 2: GSK3640254 100 mg/GSK3640254 500 mg/Moxifloxacin 400 mg/ Placebo	Participants received a single therapeutic dose of GSK3640254 100 mg Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.
BG009	Part 2: Moxifloxacin 400 mg/GSK3640254 100 mg/Placebo/GSK3640254 500 mg	Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.
BG010	Part 2: Placebo/GSK3640254 100 mg/GSK3640254 500 mg/Moxifloxacin 400 mg	Participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P) in treatment period 1. In treatment period 2, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 3, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). There was a washout period of at least 7 days between each treatment periods.
BG011	Part 2: GSK3640254 100 mg/Moxifloxacin 400 mg/Placebo/GSK3640254 500 mg	Participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 4, participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST). There was a washout period of at least 7 days between each treatment periods.
BG012	Part 2: GSK3640254 500 mg/Placebo/Moxifloxacin 400 mg/GSK3640254 100 mg	Participants received single supratherapeutic dose of GSK3640254 500 mg Days 1 through 7 (Treatment ST) in treatment period 1. In treatment period 2, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). In treatment period 3, participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M). In treatment period 4, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). There was a washout period of at least 7 days between each treatment periods.
BG013	Part 2: Moxifloxacin 400 mg/GSK3640254 500 mg/GSK3640254 100 mg/Placebo	Participants received placebo for GSK3640254 on Days 1 through 6 and a single dose of moxifloxacin 400 mg on Day 7 (Treatment M) in treatment period 1. In treatment period 2, participants received single supratherapeutic dose of GSK3640254 500 mg on Days 1 through 7 (Treatment ST). In treatment period 3, participants received a single therapeutic dose of GSK3640254 100 mg on Days 1 through 7 (Treatment T). In treatment period 4, participants received placebo for GSK3640254 on Days 1 through 7 (Treatment P). There was a washout period of at least 7 days between each treatment periods.
BG014	Total	Total of all reporting groups

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Time t (AUC[0-t]) of GSK3640254

Blood samples were collected at indicated time points. Pharmacokinetic (PK) analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Parameter Population comprised of all participants who undergone plasma PK sampling and had evaluable PK parameters estimated. Only those participants with data available at specified time points were analyzed.

Posted

Geometric Mean

Geometric Coefficient of Variation

Hours*nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

ID	Title	Description
OG000	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG0006

Title

Denominators

Categories

Title	Measurements
	OG000102400± 25.3

Primary

Part 1: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) of GSK3640254

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Geometric Mean

Geometric Coefficient of Variation

Hours*nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

ID	Title	Description
OG000	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Maximum Observed Concentration (Cmax) of GSK3640254

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Geometric Mean

Geometric Coefficient of Variation

Nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

ID	Title	Description
OG000	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Plasma Concentration at the End of the Dosing Interval (Ctau) of GSK3640254

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Geometric Mean

Geometric Coefficient of Variation

Nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

ID	Title	Description
OG000	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Time of Maximum Observed Concentration (Tmax) of GSK3640254

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Median

Full Range

Hours

Pre-dose and 30 minutes, 1 Hour, 2 Hours, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

ID	Title	Description
OG000	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Plasma Concentration of GSK3640254

Blood samples were collected at indicated time points to analyze the plasma concentration of GSK3640254.

Pharmacokinetic concentration Population comprised of all participants who undergone plasma PK sampling and had evaluable PK assay results. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

ID	Title	Description
OG000	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Plasma Concentration of Major Metabolites of GSK3640254

Blood samples were to be collected at indicated time points to analyze the plasma concentration of major metabolites of GSK3640254.

Pharmacokinetic concentration Population. Data was not collected for metabolites of GSK3640254 as there were not enough residual plasma left to analyze metabolites.

Posted

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 12 Hours, 24 Hours, 48 Hours post-dose on Day 7

ID	Title	Description
OG000	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect as per medical and scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.

Safety Population comprised of all randomized participants who received at least 1 dose of study intervention.

Posted

Count of Participants

Participants

Up to Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units

Primary

Part 1: Absolute Values for Hematology Parameter: Hemoglobin

Blood samples were collected at indicated time points to analyze hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population

Posted

Mean

Standard Deviation

Grams per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Hematology Parameter: Hematocrit

Blood samples were collected at indicated time points to analyze hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population

Posted

Mean

Standard Deviation

Proportion of red blood cells in blood

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Safety Population

Posted

Median

Standard Deviation

Femtoliter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Safety Population

Posted

Mean

Standard Deviation

Picograms

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

Blood samples were collected at indicated time points to analyze basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. .

Safety Population

Posted

Mean

Standard Deviation

10^9 cells per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Hematology Parameter: Erythrocytes

Blood samples were collected at indicated time points to analyze erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population

Posted

Mean

Standard Deviation

10^12 cells per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected at indicated time points to analyze hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population

Posted

Mean

Standard Deviation

Grams per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected at indicated timepoints to analyze hemotocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population

Posted

Mean

Standard Deviation

Proportion of red blood cells in blood

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected at indicated time points to analyze erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population

Posted

Mean

Standard Deviation

Femtoliter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected at idicated time points to analyze erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population

Posted

Mean

Standard Deviation

Picograms

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

Safety Population

Posted

Mean

Standard Deviation

10^9 cells per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants

Primary

Part 1: Change From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected at indicated time points to analyze the hematology parameter: Erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population

Posted

Mean

Standard Deviation

10^12 cells per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, and Blood Urea Nitrogen

Blood samples were collected at indicated time points to analyze glucose, cholesterol, magnesium, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium, and blood urea nitrogen. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population

Posted

Mean

Standard Deviation

Millimoles per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants

Primary

Part 1: Absolute Values for Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase (GGT), Creatine Kinase, and Lactate Dehydrogenase

Safety Population

Posted

Mean

Standard Deviation

International units per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants

Primary

Part 1: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, and Direct Bilirubin

Safety Population

Posted

Mean

Standard Deviation

Micromoles per liter

Baseline (Day -2), Day 3, Day 7, Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Chemistry Parameters: Albumin, Globulin, and Total Protein

Safety Population

Posted

Mean

Standard Deviation

Grams per liter

Baseline (Day -2), Day 3, Day 7, Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Chemistry Parameters: Amylase and Lipase

Safety Population

Posted

Mean

Standard Deviation

Units per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

Safety Population

Posted

Mean

Standard Deviation

Millimoles per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants

Primary

Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase

Blood samples were collected at indicated time points to analyze ALT, ALP, AST, GGT, creatine kinase, and lactate dehydrogenase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population

Posted

Mean

Standard Deviation

International units per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants

Primary

Part 1: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin

Blood samples were collected at indicated timepoints to analyze creatinine, urate, total bilirubin, and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population

Posted

Mean

Standard Deviation

Micromoles per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Change From Baseline in Chemistry Parameters: Albumin, Globulin, and Total Protein

Blood samples were collected at indicated timepoints to analyze albumin, globulin, and total protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value

Safety Population

Posted

Mean

Standard Deviation

Grams per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Change From Baseline in Chemistry Parameters: Amylase and Lipase

Blood samples were collected at indicated timepoints to analyze amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population

Posted

Mean

Standard Deviation

Units per liter

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Urinalysis Parameter: Specific Gravity

Urine samples were collected at indicated time points to analyze the urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population

Posted

Mean

Standard Deviation

Ratio

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Urinalysis Parameter: Potential of Hydrogen (pH)

Urine samples were collected at indicated time points to analyze the urine pH by dipstick test. The dipstick test gives results in a semi-quantitative manner indicating proportional concentrations in the urine sample. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acidic pH (5.0 - 6.0). Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population

Posted

Mean

Standard Deviation

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts

Primary

Part 1: Change From Baseline in Urinalysis Parameter: Specific Gravity

Safety Population

Posted

Mean

Standard Deviation

Ratio

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants

Primary

Part 1: Change From Baseline in Urinalysis Parameter: pH

Safety Population

Posted

Mean

Standard Deviation

Baseline (Day -2), Day 3, Day 7, and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Primary

Part 1: Number of Participants With Clinically Significant Abnormal 12-Lead Electrocardiogram (ECG) Findings

A 12-lead ECG was recorded with the participant in a supine position. 12-lead ECGs were obtained by using an automated ECG machine. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with clinically significant abnormal 12-Lead ECG findings has reported

Safety Population

Posted

Count of Participants

Participants

Baseline(Day-2), Day1: 2 Hours, 4 Hours, 6 Hours; Day 4: 2 Hours, 4 Hours, 6 Hours, Day 7: 2 Hours, 4 Hours, 6 Hours and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants

Primary

Part 1: Absolute Values for Vital Parameters: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were measured in the semi-recumbent or supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population

Posted

Mean

Standard Deviation

Millimeters (mm) of mercury

Baseline (Pre-dose, Day 1), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8 and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants

Primary

Part 1: Absolute Values for Vital Parameter: Pulse Rate

Pulse rate was measured in the semi-recumbent or supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population

Posted

Mean

Standard Deviation

Beats per minute (bpm)

Baseline (Pre-dose, Day 1), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8 and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 1: Absolute Values for Vital Parameter: Temperature

Temperature was measured in the semi-recumbent or supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions.Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Safety Population

Posted

Mean

Standard Deviation

Degrees Celsius

Baseline (Pre-dose, Day 1), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8 and Day 9

ID	Title	Description
OG000	Part 1 : Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.
OG001	Part 1 : GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.

Units	Counts
Participants	OG000

Primary

Part 2: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) Following Administration of GSK3640254 100 mg and GSK3640254 500 mg Using Concentration-QTc (C-QTc) Analysis

Twelve-lead ECGs were recorded in participant using automated ECG machine & performed with participant in supine position after a rest of at least 10 minutes.Baseline was defined as the latest pre-dose assessment with a non-missing value for each visit. Change from Baseline was calculated by subtracting Baseline value from post dose value. Placebo-corrected change from Baseline in QT interval corrected for heart rate using Fridericia's formula (QTcF) was calculated as difference in model-predicted mean change from Baseline in QTcF between treatment groups using C-QTc analysis. A linear mixed-effects model with change from Baseline in QTcF as the dependent variable, time-matched GSK3640254 plasma concentration as a fixed effect, centered Baseline as additional covariate,treatment &time as categorical factors, & a random intercept & slope per participant. In all calculations, concentrations in participants who received placebo were set to 0.

PK/QTc Population comprised of all participants who are in both QT/QTc and PK concentration Populations with at least 1 pair of post-dose PK and change from Baseline in QTc data from the same time point as well as participants in the QT/QTc Population who received placebo. Only those participants with data available at specified time points were analyzed. This outcome measure(OM) intended to provide Placebo-corrected data. Summary of change from Baseline data is provided in OM43.

Posted

Geometric Least Squares Mean

90% Confidence Interval

Milliseconds (ms)

Baseline (Pre-dose, Day 1) and up to Day 7

ID	Title	Description
OG000

Primary

Part 2: Plasma Concentration of GSK3640254

Blood samples were collected at indicated time points to analyze the plasma concentration of GSK3640254.

Pharmacokinetic Concentration Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each treatment period

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Units	Counts
Participants

Primary

Part 2: Plasma Concentration of Major Metabolites of GSK3640254

Blood samples were to be collected at indicated time points to analyze the plasma concentration of major metabolites of GSK3640254.

Pharmacokinetic concentration Population. Data was not collected for metabolites of GSK3640254 as there were not enough residual plasma left to analyze metabolites.

Posted

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each treatment period

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Units	Counts
Participants

Secondary

Part 2: Change From Baseline in Heart Rate (HR) - For GSK3640254 100 mg, GSK3640254 500 mg and Placebo Arms

QT/QTc Population comprised of all participants in the safety population with measurements at baseline as well as on-treatment with at least 1 post-dose time point with a valid change from Baseline in QTc value. Only those participants with data available at specified time points were analyzed.

Posted

Least Squares Mean

90% Confidence Interval

Beats per minute

Baseline (Pre-dose, Day 1), Day 7 : Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) - For GSK3640254 100 mg, GSK3640254 500 mg and Placebo Arms

QT/QTc Population. Only those participants with data available at specified time points were analyzed.

Posted

Least Squares Mean

90% Confidence Interval

Milliseconds

Baseline (Pre-dose, Day 1), Day 7: Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: Placebo

Secondary

Part 2: Change From Baseline in PR Interval - For GSK3640254 100 mg, GSK3640254 500 mg and Placebo Arms

QT/QTc Population. Only those participants with data available at specified time points were analyzed.

Posted

Least Squares Mean

90% Confidence Interval

Milliseconds

Baseline (Pre-dose, Day 1), Day 7: Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: Placebo

Secondary

Part 2: Change From Baseline in QRS Interval - For GSK3640254 100 mg, GSK3640254 500 mg and Placebo Arms

QT/QTc Population. Only those participants with data available at specified time points were analyzed.

Posted

Least Squares Mean

90% Confidence Interval

Milliseconds

Baseline (Pre-dose, Day 1), Day 7 : Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: Placebo

Secondary

Twelve-lead ECGs were recorded in participant using automated ECG machine & performed with participant in supine position after a rest of at least 10 minutes.Baseline was defined as the latest pre-dose assessment with a non-missing value for each visit. Change from Baseline was calculated by subtracting Baseline value from post dose value. Placebo-corrected change from Baseline in QT interval corrected for heart rate using Fridericia's formula (QTcF) was calculated as model-predicted mean change from Baseline in QTcF in GSK3640254 group minus model-predicted mean change from Baseline in QTcF in the placebo group (by-time point analysis). Time point analysis was performed based on a linear mixed-effects model: Change from Baseline in QTcF = Time + Treatment + Time*Treatment +Baseline QTcF + Period + Sequence. An unstructured covariance structure was used to specify the repeated measures (time within participant and period). A random intercept per participant was also included.

QT/QTc Population. Only those participants with data available at specified time points were analyzed. This outcome measure is intended to provide Placebo-corrected data. Placebo and treatment wise change from Baseline data is provided in outcome measure number 43.

Posted

Least Squares Mean

90% Confidence Interval

Milliseconds

Baseline (Pre-dose, Day 1), Day 7 : Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Placebo-corrected Change From Baseline in HR Following Administration of GSK3640254 100 mg and GSK3640254 500 mg

Twelve-lead ECGs were recorded in participant using an automated ECG machine. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline is defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Placebo-corrected change from Baseline in HR was calculated as model-predicted mean change from Baseline in HR in GSK3640254 group minus model-predicted mean change from Baseline in HR in the placebo group.

Posted

Least Squares Mean

90% Confidence Interval

Beats per minute

Baseline (Pre-dose, Day 1) Day 7: Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Placebo-corrected Change From Baseline in PR Following Administration of GSK3640254 100 mg and GSK3640254 500 mg

Twelve-lead ECGs were recorded in participant using an automated ECG machine. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline is defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Placebo-corrected change from Baseline in PR was calculated as model-predicted mean change from Baseline in PR interval in GSK3640254 group minus model-predicted mean change from Baseline in PR interval in the placebo group.

QT/QTc Population. Only those participants with data available at the specified time points were analyzed. This outcome measure is intended to provide Placebo-corrected data. Placebo and treatment wise change from Baseline data is provided in outcome measure number 44.

Posted

Least Squares Mean

90% Confidence Interval

Milliseconds

Baseline (Pre-dose, Day 1) Day 7: Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg

Secondary

Part 2: Placebo-corrected Change From Baseline in QRS Following Administration of GSK3640254 100 mg and GSK3640254 500 mg

Twelve-lead ECGs were recorded in participant using an automated ECG machine. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Placebo-corrected change from Baseline in QRS was calculated as model-predicted mean change from Baseline in QRS interval in GSK3640254 group minus model-predicted mean change from Baseline in QRS interval in the placebo group.

Posted

Least Squares Mean

90% Confidence Interval

Milliseconds

Baseline (Pre-dose, Day 1) Day 7: Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg

Secondary

Part 2: Number of Participants With Outlier Results for HR, QTcF, ΔQTcF, PR Interval and QRS Interval for GSK3640254 100 mg and GSK3640254 500 mg

Twelve-lead ECGs were recorded using an automated ECG machine with participant in a supine position after a rest of at least 10 minutes. Number of participants with outlier results for HR, QTcF, ΔQTcF, PR interval and QRS interval were summarized.Categorical outlier criteria was as follows:change from Baseline in QTcF (ΔQTcF) >60 ms: Increase of QTc from Baseline > 60 ms, QTcF > 500 ms:Treatment-emergent value of > 500 ms when not present at Baseline (new onset), HR < 50 bpm with a decrease in change from Baseline in heart rate (ΔHR) > 25%:Decrease of HR from Baseline >25% resulting in HR < 50 bpm, HR > 100 bpm with an increase in ΔHR > 25% :Increase of HR from Baseline >25% resulting in HR > 100 bpm, PR > 200 ms with an increase in change from Baseline in PR interval (ΔPR) > 25%:Increase of PR from Baseline > 25% resulting in PR > 200 ms, QRS > 120 ms with an increase in change from Baseline in QRS interval (ΔQRS) > 25%:Increase of QRS from Baseline > 25% resulting in QRS > 120 ms.

QT/QTc Population. Only those participants with data available at the specified time points were analyzed.

Posted

Count of Participants

Participants

Up to Day 51

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg

Secondary

Part 2: Number of Participants With Treatment Emergent Changes of T-wave Morphology and Presence of U-wave Following Administration of GSK3640254 100 mg and GSK3640254 500 mg

Twelve-lead ECGs were recorded using an automated ECG machine. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Flat T-wave=T-amplitude < 1 mm (either positive [+] or negative [-]), including flat isoelectric line, Notched T-wave (+)=Presence of notch(es) of at least 0.05 millivolt (mV) amplitude on ascending or descending arm of the positive T-wave, Biphasic= T-wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T-waves included), Normal T-wave (-)=T-amplitude that is negative, without biphasic T-wave or notches, Notched T-wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T-wave, U-waves= Presence of abnormal U-waves. Data has been reported for Flat T-wave, Notched T-wave (Positive), Biphasic, Normal T-wave (Negative), Notched T-wave (Negative) and T-U wave Fusion.

QT/QTc Population. Only those participants with data available at the specified time points were analyzed.

Posted

Count of Participants

Participants

Up to Day 51

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg

Secondary

Part 2: Placebo-corrected Change From Baseline in QTcF Following Administration of Moxifloxacin

Twelve-lead ECGs were recorded in participant using an automated ECG machine. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline is defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value. Placebo-corrected change from Baseline in QTcF was calculated as model-predicted mean change from Baseline in QTcF in moxifloxacin group minus model-predicted mean change from Baseline in QTcF in the placebo group.

Posted

Least Squares Mean

90% Confidence Interval

Milliseconds

Baseline (Pre-dose, Day 1), Day 7: Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.

Units	Counts

Secondary

Part 2: AUC(0-t) of GSK3640254 100 mg and GSK3640254 500 mg

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods .

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Geometric Mean

Geometric Coefficient of Variation

Hours*nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each Treatment Period

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Units	Counts
Participants

Secondary

Part 2: AUC(0-tau) of GSK3640254 100 mg and GSK3640254 500 mg

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Geometric Mean

Geometric Coefficient of Variation

Hours*nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each Treatment Period

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Units	Counts
Participants

Secondary

Part 2: Cmax of GSK3640254 100 mg and GSK3640254 500 mg

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Geometric Mean

Geometric Coefficient of Variation

Nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each Treatment Period

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Units	Counts
Participants

Secondary

Part 2: Ctau of GSK3640254 100 mg and GSK3640254 500 mg

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Geometric Mean

Geometric Coefficient of Variation

Nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each Treatment Period

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Units	Counts
Participants

Secondary

Part 2: Tmax of GSK3640254 100 mg and GSK3640254 500 mg

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Median

Full Range

Hours

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each Treatment Period

ID	Title	Description
OG000	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Units	Counts
Participants

Secondary

Part 2: Cmax of Moxifloxacin 400 mg

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Geometric Mean

Geometric Coefficient of Variation

Nanograms per milliliter

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each treatment period

ID	Title	Description
OG000	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.

Units	Counts
Participants	OG000

Secondary

Part 2: Tmax of Moxifloxacin 400 mg

Blood samples were collected at indicated time points. PK analysis was conducted using standard non-compartmental methods.

Pharmacokinetic Parameter Population. Only those participants with data available at specified time points were analyzed.

Posted

Median

Full Range

Hours

Pre-dose and 30 minutes, 1 Hour, 2 Hour, 3 Hours, 3 Hours 30 minutes, 4 Hours, 4 Hours 30 minutes, 5 Hours, 6 Hours, 8 Hours, 10 Hours, 12 Hours, 24 Hours post-dose on Day 7 in each treatment period

ID	Title	Description
OG000	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.

Units	Counts
Participants	OG000

Secondary

Part 2: Number of Participants With Non-SAEs and SAEs

Safety Population.

Posted

Count of Participants

Participants

Up to Day 51

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Hematology Parameter: Hemoglobin

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Grams per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG003	Part 2: GSK3640254 500 mg

Secondary

Part 2: Absolute Values for Hematology Parameter: Hematocrit

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Proportion of red blood cells in blood

Baseline (Day -2), Day 8, Day 9, Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG003

Secondary

Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Femtoliter

Baseline (Day -2), Day 8, Day 9, Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG003

Secondary

Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected at indicated time points to analyze erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Picograms

Baseline (Day -2), Day 8, Day 9, Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG003

Secondary

Part 2: Absolute Values for Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

10^9 cells per liter

Baseline (Day -2), Day 8, Day 9, Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Hematology Parameter: Erythrocytes

Blood samples were collected at indicated time points to analyze Erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

10^12 cells per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG003	Part 2: GSK3640254 500 mg

Secondary

Part 2: Change From Baseline in Hematology Parameter: Hemoglobin

Blood samples were collected at indicated time points to analyze hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Grams per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected at indicated time points to analyze hematocrit . Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Proportion of red blood cells in blood

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

Blood samples were collected at indicated time points to analyze erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Femtoliter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Picograms

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in Hematology Parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

10^9 cells per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected at indicated time points to analyze erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

10^12 cells per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Millimoles per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase

Blood samples were collected at indicated time points to analyze ALT, ALP, AST, GGT, creatine kinase, and lactate dehydrogenase. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

International units per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin

Blood samples were collected at indicated timepoints to analyze creatinine, urate, total bilirubin, and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Micromoles per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Chemistry Parameters: Albumin, Globulin, Total Protein

Blood samples were collected at indicated timepoints to analyze albumin, globulin, and total protein. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Grams per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG003

Secondary

Part 2: Absolute Values for Chemistry Parameters: Amylase and Lipase

Blood samples were collected at indicated timepoints to analyze amylase and lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Units per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG003	Part 2: GSK3640254 500 mg

Secondary

Part 2: Change From Baseline in Chemistry Parameters: Glucose, Cholesterol, Magnesium, Triglycerides, Anion Gap, Calcium, Carbon Dioxide, Chloride, Phosphate, Potassium, Sodium, Blood Urea Nitrogen

Blood samples were collected at indicated time points to analyze glucose, cholesterol, magnesium, triglycerides, anion gap, calcium, carbon dioxide, chloride, phosphate, potassium, sodium, and blood urea nitrogen.Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Millimoles per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg

Secondary

Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, Creatine Kinase, Lactate Dehydrogenase

Blood samples were collected at indicated time points to analyze ALT, ALP, AST, GGT, creatine kinase, and lactate dehydrogenase. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

International units per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in Chemistry Parameters: Creatinine, Urate, Total Bilirubin, Direct Bilirubin

Blood samples were collected at indicated timepoints to analyze creatinine, urate, total bilirubin, and direct bilirubin. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Micromoles per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in Chemistry Parameters: Albumin, Globulin, Total Protein

Blood samples were collected at indicated timepoints to analyze albumin, globulin, and total protein. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Grams per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in Chemistry Parameters: Amylase, Lipase

Blood samples were collected at indicated timepoints to analyze amylase, lipase. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visit. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Units per liter

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Urinalysis Parameter: Specific Gravity

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Ratio

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Urinalysis Parameter: pH

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg

Secondary

Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Ratio

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Change From Baseline in Urinalysis Parameter: pH

Safety Population. Only those participants with data available at specified time points were analyzed.

Posted

Mean

Standard Deviation

Baseline (Day -2), Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Number of Participants With Clinically Significant Abnormal 12-Lead ECG Findings

Safety Population.

Posted

Count of Participants

Participants

Baseline(Day-2), Day1: 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours; Day 2: 24 Hours, Day 4: 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours, Day 5: 24 Hours; Day 7: 1 Hour, 2 Hours, 3 Hours, 4 Hours, 6 Hours; Day 8: 24 Hours; Day 9 and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg

Secondary

Part 2: Absolute Values for Vital Parameters: SBP and DBP

Safety Population. Only those participants with data available at the indicated time points were analyzed.

Posted

Mean

Standard Deviation

Millimeters of mercury

Baseline (Pre-dose, Day 1), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Vital Parameter: Pulse Rate

Safety Population. Only those participants with data available at the indicated time points were analyzed.

Posted

Mean

Standard Deviation

Beats per minute

Baseline (Pre-dose, Day 1), Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Secondary

Part 2: Absolute Values for Vital Parameter: Temperature

Temperature was measured in the semi-recumbent or supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value for each period, including those from unscheduled visits.

Safety Population. Only those participants with data available at the indicated time points were analyzed.

Posted

Mean

Standard Deviation

Degrees Celsius

Baseline (Pre-dose, Day 1), Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 11, Day 12, Day 13, and Day 14

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.
OG002	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.

Other Pre-specified

Part 2: Change From Baseline in QTcF - For Placebo and Moxifloxacin Arm

QT/QTc Population. Only those participants with data available at specified time points were analyzed.

Posted

Least Squares Mean

90% Confidence Interval

Milliseconds

Baseline (Pre-dose, Day 1), Day 7: Predose and 0.5, 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24 Hours post dose

ID	Title	Description
OG000	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.
OG001	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.

Units	Counts

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 24.1	Systematic Assessment	EG0001 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG0030 affected40 at risk EG0040 affected40 at risk EG0050 affected40 at risk
Groin pain	Musculoskeletal and connective tissue disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0011 affected6 at risk EG0020 affected42 at risk EG003
Muscle spasms	Musculoskeletal and connective tissue disorders	MedDRA 24.1	Systematic Assessment	EG0001 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Somnolence	Nervous system disorders	MedDRA 24.1	Systematic Assessment	EG0001 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0021 affected42 at risk EG003
Abdominal pain	Gastrointestinal disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0021 affected42 at risk EG003
Nausea	Gastrointestinal disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Abdominal discomfort	Gastrointestinal disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Abdominal distension	Gastrointestinal disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Haemorrhoids	Gastrointestinal disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Medical device site dermatitis	General disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Vessel puncture site pain	General disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0021 affected42 at risk EG003
Chills	General disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Fatigue	General disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0021 affected42 at risk EG003
Acne	Skin and subcutaneous tissue disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Rash maculo-papular	Skin and subcutaneous tissue disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Dermatitis contact	Skin and subcutaneous tissue disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Dry skin	Skin and subcutaneous tissue disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0021 affected42 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Coronavirus infection	Infections and infestations	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0021 affected42 at risk EG003
Nasopharyngitis	Infections and infestations	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0021 affected42 at risk EG003
Trichomoniasis	Infections and infestations	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Dizziness	Nervous system disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Headache	Nervous system disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Presyncope	Nervous system disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Seasonal allergy	Immune system disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Urinary hesitation	Renal and urinary disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003
Menstruation irregular	Reproductive system and breast disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0021 affected42 at risk EG003
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	MedDRA 24.1	Systematic Assessment	EG0000 affected2 at risk EG0010 affected6 at risk EG0020 affected42 at risk EG003

ID	Term
D000086982	Blood-Borne Infections
D003141	Communicable Diseases
D007239	Infections
D015229	Sexually Transmitted Diseases, Viral
D012749	Sexually Transmitted Diseases
D016180	Lentivirus Infections
D012192	Retroviridae Infections
D012327	RNA Virus Infections
D014777	Virus Diseases
D000091662	Genital Diseases
D000091642	Urogenital Diseases
D007153	Immunologic Deficiency Syndromes
D007154	Immune System Diseases

ID	Term
D024841	Fluoroquinolones
D042462	4-Quinolones
D015363	Quinolones
D011804	Quinolines
D006574	Heterocyclic Compounds, 2-Ring
D000072471	Heterocyclic Compounds, Fused-Ring
D006571	Heterocyclic Compounds

ID	Title	Description	Deaths (At Risk)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Part 1: Placebo	Participants received a single dose of placebo once daily for 7 days following ingestion of a moderate fat meal.	2	2	2	2
EG001	Part 1: GSK3640254 500 mg	Participants received single dose of GSK3640254 500 mg once daily for 7 days following ingestion of a moderate fat meal.	6	6	1	6
EG002	Part 2: Placebo	Participants received placebo matching GSK3640254 from Days 1 through 7 in each Treatment Period of Part 2 of the study.	42	42	7	42
EG003	Part 2: Moxifloxacin 400 mg	Participants received placebo matching GSK3640254 from Days 1 through 6 and a single dose of Moxifloxacin 400 mg on Day 7 in each Treatment Period of Part 2 of the study.	40	40	4	40
EG004	Part 2: GSK3640254 100 mg	Participants received therapeutic dose of GSK3640254 100 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.	40	40	5	40
EG005	Part 2: GSK3640254 500 mg	Participants received supratherapeutic dose of GSK3640254 500 mg once daily from Days 1 through 7 in each Treatment Period of Part 2 of the study.	40	40	10	40